JPMorgan Chase & Co. Boosts Twist Bioscience (NASDAQ:TWST) Price Target to $40.00

Twist Bioscience (NASDAQ:TWST) had its price objective increased by equities research analysts at JPMorgan Chase & Co. from $35.00 to $40.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential downside of 25.46% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the company. Wolfe Research assumed coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Barclays lowered their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Scotiabank boosted their price objective on Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $53.66 on Tuesday. The stock has a fifty day moving average of $48.74 and a 200 day moving average of $46.27. Twist Bioscience has a 52-week low of $27.41 and a 52-week high of $60.90. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -14.91 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The business’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.75) EPS. Equities analysts forecast that Twist Bioscience will post -2.27 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In related news, COO Patrick John Finn sold 10,340 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00. Following the completion of the sale, the chief operating officer now owns 221,061 shares in the company, valued at $10,610,928. This represents a 4.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,002 shares of company stock worth $2,851,681. 3.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience in the third quarter worth about $34,000. Van ECK Associates Corp lifted its holdings in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares during the last quarter. Signaturefd LLC increased its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. US Bancorp DE boosted its position in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares during the period. Finally, Beaird Harris Wealth Management LLC bought a new position in Twist Bioscience in the 3rd quarter worth about $95,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.